The nuances of immunotherapy for NORSE/FIRES
- PMID: 36266948
- DOI: 10.1111/epi.17439
The nuances of immunotherapy for NORSE/FIRES
References
REFERENCES
-
- Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) incl. Febrile infection-related epilepsy syndrome (FIRES): statements and supporting evidence. Epilepsia. 2022:1-25. https://doi.org/10.1111/epi.17397
-
- Wickstrom R, Taraschenko O, Dilena R, Payne ET, Specchio N, Nabbout R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): summary and clinical tools. Epilepsia. 2022:1-13. https://doi.org/10.1111/epi.17391
-
- Lai YC, Muscal E, Wells E, Shukla N, Eschbach K, Hyeong Lee K, et al. Anakinra usage in febrile infection related epilepsy syndrome: an international cohort. Ann Clin Transl Neurol. 2020;7(12):2467-74.
-
- Jun JS, Lee ST, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018;84(6):940-5.
-
- Lin WS, Hsu TR. Hypothesis: febrile infection-related epilepsy syndrome is a microglial NLRP3 inflammasome/IL-1 axis-driven autoinflammatory syndrome. Clin Transl Immunology. 2021;10(6):e1299.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
